News & Updates
Filter by Specialty:
Gemcitabine for IR-NMIBC tied to more recurrence vs BCG
Treatment-naive patients with immediate-risk (IR) nonmuscle-invasive bladder cancer (NMIBC) who received gemcitabine appear to have greater recurrence risk than those given Bacillus Calmette-Guerin (BCG). Both treatments, however, are effective against disease progression.
Gemcitabine for IR-NMIBC tied to more recurrence vs BCG
06 Jun 2025
VIDEO: Apalutamide’s tolerability in prostate cancer patients
Dr Darren Poon, Specialist in Clinical Oncology at Hong Kong Sanatorium & Hospital and Honorary Clinical Associate Professor at the Chinese University of Hong Kong, discusses apalutamide’s tolerability in prostate cancer patients.
VIDEO: Apalutamide’s tolerability in prostate cancer patients
19 May 2025
Nerve-sparing technique preserves erectile function after RARP
A nerve-sparing technique decreases erectile dysfunction in men undergoing robot-assisted radical prostatectomy (RARP) for prostate cancer in a phase III study.
Nerve-sparing technique preserves erectile function after RARP
13 May 2025
Rectal spacer relieves GI issues following RT for prostate cancer
In a large retrospective study, the incidence of bowel disorders and related procedures dropped when a polyethylene glycol-based hydrogel spacer (PHS) was used in men undergoing radiotherapy (RT) for prostate cancer.
Rectal spacer relieves GI issues following RT for prostate cancer
08 May 2025
LHRH analogues vs tE2 patches: Which work best for prostate cancer?
The use of transdermal oestradiol (tE2) or oestrogen patches helps suppress testosterone and prostate-specific antigen (PSA) in men with locally advanced prostate cancer, with similar efficacy to that of luteinizing hormone-releasing hormone (LHRH) analogues, reports a study presented at EAU 2025.